A detailed history of Pathstone Family Office, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Pathstone Family Office, LLC holds 2,870 shares of NBIX stock, worth $360,615. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,870
Holding current value
$360,615
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$94.02 - $117.1 $269,837 - $336,077
2,870 New
2,870 $322,000
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $3,521 - $4,192
33 Added 1.6%
2,091 $249,000
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $189,397 - $221,872
2,058 New
2,058 $219,000
Q4 2017

Feb 12, 2018

SELL
$58.53 - $77.59 $14,632 - $19,397
-250 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $11,992 - $15,320
250
250 $15,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.